Trials / Completed
CompletedNCT01133158
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
Detailed description
Assess the combination of efficacy and safety of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma who are refractory or in relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab, Bendamustine, Mitoxantrone, Dexamethasone | Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2013-12-01
- Completion
- 2016-07-01
- First posted
- 2010-05-28
- Last updated
- 2018-11-01
- Results posted
- 2018-11-01
Locations
41 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01133158. Inclusion in this directory is not an endorsement.